

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

**(1) POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON JUNE 27, 2025;**

**(2) RETIREMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTOR; AND**

**(3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTOR AND CHANGE IN COMPOSITION OF
THE BOARD COMMITTEES**

Reference is made to the circular dated June 5, 2025 (the “**Circular**”) incorporating, amongst others, the notice dated June 5, 2025 (the “**AGM Notice**”) of the annual general meeting (the “**AGM**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular and the AGM Notice.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that at the AGM held on June 27, 2025, all proposed resolutions as set out in the AGM Notice were duly passed by the Shareholders by way of poll.

**(1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE
27, 2025**

As at the date of the AGM, the total number of issued shares of the Company was 2,412,592,839 shares. There was no treasury Shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury Shares have been exercised at the AGM. As stated in the Circular, MicroPort Scientific Corporation (through its wholly-owned subsidiary Shanghai

MicroPort Limited, indirectly holding 1,112,855,680 Shares, representing approximately 46.13% of the issued Shares of the Company as of the date of the AGM) and its associates were required to abstain, and had abstained from voting on the ordinary resolutions numbered 6(i) and 6(ii) at the AGM. Save as disclosed above, no Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the AGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rules 13.40 and 14A.36 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

All the Directors, namely Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying as the executive Directors, Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia as the non-executive Directors, and Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang as the independent non-executive Directors attended the AGM either in person or by electronic means.

The poll results in respect of each resolution proposed at the AGM were as follow:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and the auditor of the Company for the year ended December 31, 2024	1,283,808,114 100.000000%	0 0.000000%
2.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of the issued share capital of the Company (excluding treasury shares)	1,283,808,114 100.000000%	0 0.000000%
3.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company not exceeding 20% of the total number of the issued share capital of the Company (excluding treasury shares)	1,270,703,165 98.979213%	13,104,949 1.020787%
4.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the shares to be bought back by the Company	1,270,703,165 98.979213%	13,104,949 1.020787%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
5.	(i) To re-elect Mr. Chen Guoming as a non-executive Director	1,250,517,008 97.406847%	33,291,106 2.593153%
	(ii) To re-elect Mr. Zhang Ruinian as an executive Director	1,250,517,478 97.406884%	33,290,636 2.593116%
	(iii) To re-elect Mr. Zhao Liang as an executive Director	1,250,578,973 97.411674%	33,229,141 2.588326%
6.	(i) To consider and approve the Equity Transfer Agreement dated May 30, 2025, and the transaction contemplated thereunder	170,952,434 100.000000%	0 0.000000%
	(ii) To consider and authorize such further acts and things and to sign and execute all such other or further documents or agreements and to take all such steps which, in the opinion of the Directors (or a duly authorized committee thereof), may be necessary, appropriate, desirable or expedient to implement and/or give effect to the terms of, or the transaction contemplated by the Equity Transfer Agreement and to agree to such variation, amendments or waiver of matters relating thereto as are, in the opinion of the Directors (or a duly authorized committee thereof), in the interests of the Company	170,952,434 100.000000%	0 0.000000%
7.	To authorise the Board to fix the remuneration of the Directors	1,274,129,856 99.246129%	9,678,258 0.753871%
8.	To re-appoint KPMG as the auditor of the Company and authorize the Board to fix its remuneration	1,283,808,114 100.000000%	0 0.000000%

Note: The full text of the above resolutions are set out in the AGM Notice.

As more than 50% of votes were cast in favour of all the ordinary resolutions nos. 1 to 8 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

(2) RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Ding Jiandong (“**Dr. Ding**”) retired as an independent non-executive Director with effect from the conclusion of the AGM and did not offer himself for re-election at the AGM as disclosed in the Circular. Accordingly, Dr. Ding ceased to act as a member of each of the audit committee (the “**Audit Committee**”) and nomination committee of the Company (the “**Nomination Committee**”) with effect from the conclusion of the AGM.

Dr. Ding has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its appreciation to Dr. Ding for his valuable contributions to the Company during his tenure of office with the Board and the Company.

(3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

The Board is also pleased to announce that Dr. Hu Bingshan (胡冰山) (“**Dr. Hu**”) has been appointed as an independent non-executive Director and a member of each of the Audit Committee and Nomination Committee, with effect from June 27, 2025 following the retirement of Dr. Ding. The biographical details of Dr. Hu are set out below:

Dr. Hu, aged 43, has successively served as associate professor and professor at the University of Shanghai for Science and Technology (上海理工大學) since November 2016. His main research field is rehabilitation and nursing robotics. From October 2010 to November 2016, Dr. Hu worked as a space robotics systems engineer at the Shanghai Aerospace System Engineering Institute in the China Aerospace Science and Technology Corporation (中國航天科技集團公司上海宇航系統工程研究所). In 2015, he also served as a visiting scholar at the University of Hamburg in Germany. Dr. Hu serves as a committee member for the Sports Health and Industry Promotion Committee of China Association of Rehabilitation Medicine (中國康復醫學會運動健康與產業發展專委會) and other relevant academic organizations. He received the First Prize and the Second Prize of Science and Technology from the China Association of Rehabilitation Medicine (中國康復醫學會) in October 2023 and in September 2024, respectively. Dr. Hu has published more than 50 papers in internationally recognized journals or academic conferences. He is also an inventor or co-inventor of more than 70 Chinese and overseas patents.

Dr. Hu received his bachelor’s degree in electrical engineering and automation and his master’s degree in power electronics and electric drives from Harbin University of Science and Technology (哈爾濱理工大學) in July 2003 and April 2006, respectively, and obtained his Ph.D. in mechatronic engineering from Shanghai Jiao Tong University (上海交通大學) in December 2010.

Dr. Hu has entered into a letter of appointment with the Company. The initial term of his appointment letter shall commence from the effective date of his appointment for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to his letter of appointment, he is entitled to an annual director's fee of RMB200,000. Dr. Hu's remuneration will be subject to annual review by the remuneration committee of the Company and the Board from time to time with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

Dr. Hu shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Dr. Hu confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any other major appointments and professional qualifications; (iii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Dr. Hu has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Dr. Hu that need to be brought to the attention of the Shareholders.

The Board would like to welcome Dr. Hu for joining as a member of the Board.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, June 27, 2025

As at the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.